Big on promise, big on cost: Which patients warrant this cholesterol-busting wonder drug?

Emily Dunn
Red blood cells

Meet the new lipid-lowering agents: monoclonal antibodies that promise to shrink LDL to levels lower than even the strongest statin could achieve.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have captured attention for their potential to cut stroke and myocardial infarction risk, as well as for their substantial cost, an estimated $8000 per year.